Organovo (ONVO) FY14 Revenues: collaborations/grants: $0.4M; product: $0; SG&A expenses: $13.1M; R&D expenses: $8M; net loss: ($25.8M); loss/share: ($0.35); CF Ops: ($15.6M); cash & equivalents: $48.2M.
YOY comparisons are not included because management chose to not to disclose FY13 results. In the income and cash flow statements, it lists results for FY14, FY12 and FY11 but not FY13. Fiscal Q4's results aren't listed either, just Q413 vs Q412.
Management's obfuscation in its reporting underscores its controversial nature. It undermines management's credibility and lends credence to bears' view that its long-term value proposition of printing human organs is a myth.